Fig. 4: ALFQ-adjuvanted recombinant gp120 and mRNA-LNP-encoded gp120 immunizations in macaques elicit similar magnitudes of plasma antibodies capable of blocking ADCC-mediating antibodies, HIV-1 bnAbs, and CD4 binding to Env. | npj Vaccines

Fig. 4: ALFQ-adjuvanted recombinant gp120 and mRNA-LNP-encoded gp120 immunizations in macaques elicit similar magnitudes of plasma antibodies capable of blocking ADCC-mediating antibodies, HIV-1 bnAbs, and CD4 binding to Env.

From: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates

Fig. 4

a–e Plasma antibody blocking of (a) ADCC-mediating antibodies (CH58 and A32), b N332 glycan bnAbs (2G12 and PGT125), c, d V2-glycan CH01, PG9), and e soluble CD4. Antibody and Env names are listed in the graph title. Note, plasma IgG blocking is absent when non-vaccine matched Envs 9021 or B.6240 are used as the Env antigen in (d). The group mean and standard error are shown (n = 5 per group). Arrows indicate immunization timepoints.

Back to article page